PMA Decision Times Edged Upward, Likely Due To More Advisory Panels
This article was originally published in The Gray Sheet
The total time to decision seems to have increased for original PMAs submitted in FY 2013 based on interim data. The upward trend may be due to an unusually high proportion of advisory panels scheduled for that cohort of applications, which FDA believes is settling back to normal for FY 2014 applications.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.